Example: Heart Attack

Search clinical trials for: Abacavir

Total 232 results

NCT04493216

Not yet recruiting

A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults

Conditions: HIV Infections
NCT04340388

Not yet recruiting

Contribution of Dolutegravir to Obesity and Cardiovascular Disease

Conditions: HIV-1-infection; Antiviral Drug Adverse Reaction; Vascular Diseases; Cardiovascular Abnormalities; Abnormality of Adipose Tissue; Body Weight Changes; Body Fat Disorder; HIV-Associated Lipodystrophy Syndrome
NCT04301661

Recruiting

Cellular Pharmacology and Platelet Effects of Abacavir and Lamivudine Anabolites

Conditions: HIV-1-infection
NCT04155554

Recruiting

Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based Regimen

Conditions: HIV-1-infection
NCT04012931

Recruiting

A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed

Conditions: HIV
NCT03836833

Recruiting

Lopinavir/r/ Lamivudine/ Abacavir as an Easy to Use Paediatric Formulation

Conditions: HIV
NCT03760458

Recruiting

The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age

Conditions: HIV Infections
NCT03685500

Recruiting

A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c)

Conditions: HIV Infections
NCT03656783

Recruiting

Effects of Biktarvy on CFR in Stable HIV Patients

Conditions: HIV
NCT03631732

Active, not recruiting

Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

Conditions: HIV-1 Infection
NCT03602690

Recruiting

Evaluation of Third-line cART Regimen in Cambodia (3DICAM)

Conditions: HIV/AIDS
NCT03447873

Unknown status

Tripe Versus Dual Antiretroviral Therapy in HIV-infected Patients With Virological Suppression (Tridual)

Conditions: HIV Infections
NCT03360682

Active, not recruiting

Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV‐1‐Infected Solid Organ Transplant Patients

Conditions: HIV-1-infection; Solid Organ Transplant
NCT03327740

Completed

PRJ2203: Dolutegravir Post Authorization Safety Study (PASS)

Conditions: Infection, Human Immunodeficiency Virus I
NCT03316534

Completed

Effect of Aspirin on Abacavir-induced Platelet Reactivity in HIV-infected Patients

Conditions: HIV-infected Patients
NCT03284645

Active, not recruiting

Viral and Antiretroviral Dynamics in HIV-1 Mother-to-Child Transmission Fluids

Conditions: Human Immunodeficiency Virus Infection
NCT03256422

Active, not recruiting

Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients

Conditions: HIV Infections
NCT03224338

Completed

Dolutegravir Plus 2 NRTIs, in Treatment-Naïve HIV-2 Infected Subjects

Conditions: HIV II Infection
NCT03178084

Completed

Effects of Maraviroc vs. Efavirenz on CD4/CD8 Ratio

Conditions: HIV/AIDS
NCT03081572

Recruiting

Platelet Function on Abacavir and Tenofovir

Conditions: Cardiovascular Diseases; Platelet Aggregation, Spontaneous; HIV/AIDS
NCT03067285

Completed

A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study

Conditions: HIV Infections
NCT02995824

Completed

Effectiveness of Raltegravir-Based Antiretroviral Therapy in HIV-HCV Coinfected Liver Transplant Recipients

Conditions: Liver Transplantation; HIV Infections; Antiretroviral Therapy
NCT02957864

Recruiting

Switching From Tenofovir Disoproxil Fumarate to Abacavir or Tenofovir Alafenamide

Conditions: Renal Insufficiency,Chronic; Hiv; Therapeutic Agent Toxicity
NCT02938520

Active, not recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

Conditions: HIV Infections
NCT02924389

Suspended

Dolutegravir in Reservoirs

Conditions: HIV
NCT02893488

Completed

Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet

Conditions: Infection, Human Immunodeficiency Virus
NCT02868580

Completed

Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS).

Conditions: Amyotrophic Lateral Sclerosis
NCT02708342

Completed

Observational, Retrospective Analysis in HIV-1 Infected Patients. (ORASWIRAL)

Conditions: HIV
NCT02659761

Recruiting

Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject Drugs

Conditions: Human Immunodeficiency Virus
NCT02607930

Active, not recruiting

Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naïve Adults

Conditions: HIV-1 Infection
NCT02605954

Completed

Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

Conditions: HIV-1 Infection
NCT02603107

Completed

Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

Conditions: HIV-1 Infection
NCT02596334

Terminated

Study to Evaluate the Efficacy of MONotherapy of TiviCAY® Versus a Triple Therapy in HIV-1-infected Patients

Conditions: HIV
NCT02588820

Unknown status

Impact of Extremely Early Antiretroviral Therapy to Reduce VIral REservoir and Induce Functional CURE of HIV-1 Infection

Conditions: HIV Infections
NCT02569346

Completed

Bioequivalence Study of CRushed TriUMeq With or Without Drip Feed Compared to the Whole Tablet

Conditions: HIV
NCT02556268

Completed

Interaction With HIV Antiretroviral Agents

Conditions: HIV-DDI
NCT02539576

Completed

Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects

Conditions: Infection, Human Immunodeficiency Virus
NCT02513147

Completed

HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen

Conditions: HIV-1
NCT02509195

Completed

SSAT064: Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over

Conditions: HIV
NCT02486133

Completed

Dual Therapy With Boosted Darunavir + Dolutegravir

Conditions: HIV-Infection
NCT02470650

Unknown status

Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive

Conditions: Patient Compliance; Antiretroviral Therapy Intolerance
NCT02384395

Active, not recruiting

Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection

Conditions: HIV; Acute HIV Infection
NCT02363452

Completed

Reverse Transcriptase Inhibitors in AGS

Conditions: Aicardi-Goutières Syndrome (AGS)
NCT02342769

Completed

Prospective Non-Interventional Observational Study of Use of TRIUMEQ and Corresponding Monitoring Measures in Clinical Practice in Germany

Conditions: HIV Infections
NCT02337322

Unknown status

Immune Recovery in Advanced , ARV-naïve, HIV-1-infected Individuals Taking Dolutegravir or Ritonavir-boosted Darunavir

Conditions: Acquired Immune Deficiency Syndrome Virus
NCT02285374

Unknown status

Efavirenz to Dolutegravir Switch in Patients With CNS Toxicity

Conditions: HIV
NCT02275780

Active, not recruiting

Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)

Conditions: HIV-1
NCT02246998

Completed

Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults

Conditions: HIV-1 Infection
NCT02182765

Terminated

Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine, Abacavir and Amprenavir in HIV-1 Infected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Naive Adults

Conditions: HIV Infections
NCT02159599

Completed

Study to Evaluate Darunavir/Ritonavir + Lamivudine Versus Continuing With Darunavir/Ritonavir + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected Subject

Conditions: HIV Infection